Navigation Links
Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
Date:3/10/2009

measured at 2 hours after the first dose. Both the 5 mg and 10 mg doses of AZ-004 met these primary and secondary endpoints. All results were considered statistically significant at the p < 0.05 level, as compared to placebo, and all statistical analyses were made on an intent-to-treat basis. The 10 mg dose of AZ-004 exhibited a rapid onset of effect, with statistically significant reduction in agitation at 10 minutes post-dose, the first time point measure in the study. The reduction of agitation was generally sustained through the 24-hour study period. Various additional assessments of a patient's agitation state were conducted at serial time points using the PEC score over the first 4-hour post-dose time period, with follow-up assessments at the end of the 24-hour study period. Side effects were recorded for each patient throughout the clinical trial period. The administration of AZ-004 was generally safe and well tolerated. The most common side effect, and the only side effect reported by at least 10% of the patients in any treatment group, was taste. This side effect was rated as mild in all patients.

In September 2008, the Company announced positive results from its first Phase 3 clinical trial of AZ-004 in 344 acutely agitated schizophrenic patients. The study design was similar to the clinical trial outlined above. Both the 5 mg and the 10 mg doses of AZ-004 met the primary and secondary endpoints of the study. The administration of AZ-004 was generally safe and well tolerated in this patient population.

AZ-004 has been licensed to Symphony Allegro, Inc., or Symphony Allegro, and the Company has the right to repurchase all rights to this product candidate.

  • AZ-104 (Staccato loxapine). Alexza is developing AZ-104 to treat patients suffering from acute migraine headaches. AZ-104 is a lower dose version of AZ-004. In January 2009, Alexza initiated an AZ-104 outpati
    '/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference
2. Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009
3. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
4. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
5. Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
6. Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008
7. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
8. Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
9. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
10. Alexzas Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
11. Alexza to Webcast Investor and Analyst Day Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Sleep apnea may make it ... you parked your car or left your house keys, a ... sleep apnea showed that this ability -- called spatial memory ... (REM) sleep, even when other stages of sleep weren,t affected. ... dreams typically occur. "We,ve shown for the first time ...
(Date:10/31/2014)... say that either they or a family member have ... latest issue of The Gerontological Society of America,s ... which goes on to show that Americans strongly support ... end-of-life health care wishes. , This PP&AR , ... features 12 articles that present new ways of understanding ...
(Date:10/31/2014)... New York (PRWEB) October 31, 2014 ... Mineola Eye in Garden City, Long Island and the ... to their medical staff, according to North Shore Eye ... is the Emeritus Acting Chairman of the Department of ... and successful practice in Garden City for more than ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 FindSurrogateMother.com ... most remarkable gifts of life — building a family ... extraordinary surrogate mothers and donors with hopeful intended parents ... unforeseen circumstances. , It’s a collective aptitude of surrogate ... surrogacy lawyers, and fertility clinics that help provide these ...
(Date:10/31/2014)... 31, 2014 BCC Research ( http://www.bccresearch.com ) ... QUALITY MARKET , the U.S. indoor air quality (IAQ) market ... a compound annual growth rate (CAGR) of 7% over the ... grow at a CAGR of 7.4%. , Since 2012, ... mold, the outbreak of infectious diseases such as bird flu ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3
... A study was conducted by Nathan Thielman, M.D, Duke University ... effective in preventing HIV infections than those which charge a ... testing center and is therefore a very efficient method. ... free testing was conducted by The Duke researchers. Before that ...
... Plans have been announced by the Indian Government to ... which will highlight the achievements of Indian Scientists, //in ... science. The name of the new initiative of the ... for producing a one-hour film and 15 two-minute shorts ...
... most common cancer next to breast cancer in women and ... of cervical cancer would help in early treatment //and help ... cytologic screening test known as Pap smear test is used ... state and could detect early diagnosis. Women above the age ...
... have committed suicide five months ago using a lethal dose of ... degenerative disease// which made her life very traumatic and she had ... to escape from her traumatic pain so she went to Dignitas ... Irwin and Jessica Reid. ,Mrs. Jessica Reid who accompanied ...
... Bio-functional garments like stockings with aloe vera, T-shirts with ... been developed as the textile industry takes its cue ... garments an additional function in addition to keeping the ... their promises is a contentious matter. Experts also fear ...
... bond exists among siblings, even though they compete with each ... parents. The relationship which exists between siblings is very // ... do not welcome the birth of a new baby in ... among siblings. Their relationship has become more like partnerships, partly ...
Cached Medicine News:Health News:Free HIV Tests Brings Crowd to the Testing Centers 2Health News:Scented Garments Hit The Market 2
(Date:10/31/2014)... 2014 /CNW Telbec/ - Ergoresearch Ltd ("Ergoresearch" ... for accelerated growth in terms of sales and profitability. ... $17,862,341. Net income amounted to $1,230,153. The EBITDA reached ... time in the Company,s history. With the ... forces of its subsidiaries, merging in September 2014 Clinique ...
(Date:10/31/2014)... 2014 Research ... of the  "Process Validation in the US and ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics to ... Approach to Process Validation for Pharmaceutical and Biopharmaceutical ... FDA Process Validation Guidance EU Process ...
(Date:10/31/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... , Isis Pharmaceuticals, Third Quarter 2014 Financial Results and ... 11:30 a.m. ET / 8:30 a.m. PTWhere: , ... Simply log onto our website listed above. If you ... replay of the webcast will be available for a ...
Breaking Medicine Technology:Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3
... Jan. 19, 2012 /PRNewswire/ --  Terumo Cardiovascular Systems announced ... with LAAx, Inc. to distribute the TigerPaw® System II, ... The TigerPaw System II is indicated ... visualization, in conjunction with other open cardiac procedures.  It ...
... SAN DIEGO, Jan. 19, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... an underwritten public offering of 9,500,000 shares of its ... $8.10 per share. The gross proceeds to Neurocrine from ... other offering expenses payable by Neurocrine, are expected to ...
Cached Medicine Technology:Terumo Cardiovascular Systems Becomes Exclusive U.S. Distributor for TigerPaw® System II, Left Atrial Appendage Closure Device 2Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock 2Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: